RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA

• Status: Active, not recruiting
• Trial end date: 2024-10-30

Summary

This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma.

The drugs involved are:

• Rituximab

• Utomilumab

• Avelumab

• Phase: Phase 1

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborator: Pfizer
• Treatments: Antibodies, Monoclonal; Avelumab; Rituximab